Company Supported Sessions

​​Thursday, May 4, 2017


PIPELINE RESEARCH SESSION ON MDS AND MYELOID MALIGNANCIES

4 may 2017, 13:15-14:45, auditorium 2

Programme moderator: 
Prof. Guillermo Sanz 

13:15-13:30
Astex
Harold Keer

13:30-13:45
Takeda
Douglas Vincent Faller

13:45-14:00
Syros
David A. Roth

14:00-14:15
Jazz Pharmaceuticals
Arthur Louie

14:15-14:30
Incyte
Ekaterine Asatiani

14:30-14:45
Celgene
Han Myint


Effective management of disease-related cytopenias and associated risks in patients with MDS 

industry SUPPORTED session by novartis

4 May 2017, 19:30–20:30, Auditorium 3

Programme chair: 
Dr. John Porter

Faculty: 
Dr. Uwe Platzbecker, Dr Pierre Fenaux 

19:30–19:35 
Welcome and introductions
John Porter

19:35–19:50
Managing risks of thrombocytopenia in MDS patients. Do TPO-R agonists have a role?
Pierre Fenaux

19:50–20:05
Labile iron overload as a potential risk factor in the setting of allogeneic HSCT
Uwe Platzbecker

20:05–20:20
Managing risks of anemia and blood transfusions. Is it time to reconsider the role of iron chelation?
John Porter

20:20–20:30
Q&A and meeting close
Moderated by John Porter


Friday, May 5, 2017


​The future of MDS treatment: using molecular biology to personalise medicine

INDUSTRY SUPPORTED SESSION BY celgene

5 may, 2017, 13:45-14:45, Auditorium 1

Programme chair: 
Prof. Valeria Santini 

13:45-13:55
Welcome and introduction 

Valeria Santini 

13:55-14:10
The importance of molecular screening: how can mutational data inform treatment for MDS patients?
Rafael Bejar

14:10-14:25
Mutant IDH as a target in MDS: a review of the data
Eytan Stein

14:25-14:40
SF3B1 and spliceosome mutations as a target in MDS: a review of the data
Uwe Platzbecker

14:10-14:45
Closing Remarks
Valeria Santini 


Keep Me Updated